Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

Table 5 TEAEs associated with migraine attacks treated with lasmiditan in combination with triptans during the OLE

Period of triptan use relative to lasmiditan administration	Migraine attacks with TEAEs, n (%)^a
Period of triptan use relative to lasmiditan administration	Lasmiditan 50 mg	Lasmiditan 100 mg	Lasmiditan 200 mg	Total
From 24 h to immediately prior to lasmiditan administration	n = 10 2 (20.0)	n = 72 24 (33.3)	n = 30 6 (20.0)	n = 112 32 (28.6)
From 0 to < 2 h after lasmiditan administration	n = 15 1 (6.7)	n = 41 17 (41.5)	n = 8 2 (25.0)	n = 64 20 (31.3)
From 2 to < 24 h after lasmiditan administration	n = 39 11 (28.2)	n = 228 97 (42.5)	n = 98 29 (29.6)	n = 365 137 (37.5)

N number of migraine attacks treated with lasmiditan in combination with triptans, n, number of migraine attacks with events meeting specified criteria, OLE open-label extension, TEAE treatment-emergent adverse event
^aPercentages were calculated based on the number of migraine attacks with TEAEs divided by the total number of migraine attacks that required the administration of triptans at each dose level. Lasmiditan dose groups correspond to the dose used concomitantly with the triptan to treat the attacks

ISSN: 1129-2377